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Background
Although over 60 years have elapsed since the emergence 
of life-saving glucocorticoid replacement therapy for 
Addison’s disease, multiple challenges relating to its 
diagnosis and management remain.1 Several recent studies 
have confirmed that the survival rate, despite glucocorticoid 
and mineralocorticoid replacement, is not normal, with the 
accelerated mortality being attributed to cardiovascular and 
cerebrovascular disease.2,3
Epidemiology
There is a paucity of information as to the epidemiology of 
Addison’s disease from the developing world. Addison’s 
disease occurs in 39-144 people per million people in 
the Western world.4-6 However, a recent South African 
Addison’s study that sought to identify every case found the 
prevalence to be 3.1 per million. Whether patients may be 
dying with the disease undiagnosed or whether the disease 
is less common in South Africa is uncertain. In this study of 
South African Addison’s disease patients, autoimmunity as 
the underlying aetiology occurred in exclusively white and 
mixed-ancestry patients.7 
Clinical presentation
Acute primary adrenal insufficiency is characterised by 
orthostatic hypotension, agitation, confusion, circulatory 
collapse, abdominal pain and fever. Acute adrenal 
decompensation is caused by haemorrhage per se or, 
rarely, by bleeding into metastases of the adrenal glands, 
often precipitated by coexistent acute infection leading to 
death if left untreated.8,9 
The diagnosis of chronic primary adrenal insufficiency 
is frequently preceded by a history of prolonged 
hyperpigmentation, malaise, fatigue, anorexia, weight 
loss, gastrointestinal disturbance, and joint and back 
pain. Patients may crave salt and develop unusual food 
preferences, such as drinking pickling brine.10 
Hyperpigmentation is the most frequently encountered 
symptom. It is more easily recognised in the sun-exposed 
areas of the face, neck and arms, and it also occurs on areas 
that are subject to trauma, such as the knees and knuckles. 
However, hyperpigmentation may be more difficult to 
recognise in darker-skinned races, as the palmar creases 
and mucous membranes are often normally pigmented.8 
Extensive or progressive hyperpigmentation at any of these 
sites should alert clinicians to the possibility of Addison’s 
disease. However, increasing pigmentation of the skin is 
not diagnostic of primary hypoadrenalism.6 Scalp hair may 
also become darker, new naevi may be observed11 and 
calcification of the cartilage of the ear may occur.12 
Hyponatraemia, hypoglycaemia, hyperkalaemia, unex-
plained eosinophilia and mild prerenal azotaemia are, 
together, highly suggestive of primary hypoadrenalism.5,13 
Although the finding of recurrent hypoglycaemia in a type 
1 diabetic should alert a clinician to the possibility of 
Addison’s disease, it is an uncommon cause of recurrent 
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hypoglycaemia (1%).14,15 In the South African cohort, similar 
to other studies, hyperpigmentation, nausea, vomiting and 
weight loss were the most prominent features.16,17
Screening for primary adrenal failure
The adrenal cortex, responsible for the release of cortisol 
and androgens, is under the negative feedback control of 
adrenocorticotropic hormone (ACTH), while the release of 
aldosterone is controlled by the renin-angiotensin II system. 
Progressive functional deterioration, as in autoimmune 
destruction of the adrenal cortex, results in diminished 
functional adrenal reserve, as shown by reduced plasma 
concentration of cortisol and aldosterone in association 
with an increased ACTH and renin release.18 
The short synthetic ACTH stimulation test is regarded 
as the most reliable diagnostic test for chronic adrenal 
hypofunction. Synthetic ACTH can be injected intravenously 
or intramuscularly,19,20 but the dosage used, whether 1 µg 
or 250 µg, is vastly supraphysiological. Nevertheless, the 
250 µg ACTH stimulation test provides the best sensitivity 
and specificity for confirmation of primary adrenal 
insufficiency. Subjects who have either basal or stimulated 
cortisol levels in excess of 500 nmol/l, do not have overt 
Addison’s disease.1,20 However, when an early morning 
(between 07h00 and 09h00) plasma cortisol is less than 
165 nmol/l and a simultaneously taken plasma ACTH is 
elevated, no further confirmatory test is needed.1 
The short synthetic ACTH stimulation test can also be 
used to diagnose secondary hypoadrenalism. With 
regard to the dose of ACTH to be used, a meta-analysis 
showed that the low-dose (1 µg) and the standard-dose 
(250 µg) ACTH stimulation test performed similarly, but the 
receiver operating curves using the 1 µg performed slightly 
superiorly in ruling out hypothalamic-pituitary adrenal 
axis insufficiency. However, the differences were clinically 
unimportant.21 
Betterle et al proposed that subclinical autoimmune 
adrenalitis may evolve through three defined stages: stage 
1, when both ACTH and basal plasma cortisol levels are 
normal, with concomitant elevated plasma renin activity 
and reduced or normal aldosterone levels; stage 2, when 
ACTH levels are normal but the peak stimulated plasma 
cortisol level is reduced; and stage 3, when the ACTH level 
is elevated through compensation but the basal plasma 
cortisol is reduced. Should stress, surgery, pregnancy, 
infection or trauma coexist in stage 3 of subclinical disease, 
overt clinical hypoadrenalism may manifest. Adrenal cortical 
mass declines throughout these predetermined subclinical 
stages.18 Subclinical hypoadrenalism should be considered 
when the ratio of ACTH (pmol/l) to cortisol (nmol/l) is 
increased to greater than 0.028.22 This is evident in early 
autoimmune primary adrenal insufficiency, when patients 
exhibit reduced sensitivity to low-dose ACTH stimulation.23 
Patients with autoimmune polyglandular syndromes 
(APS) without Addison’s disease are at increased risk 
of subsequently developing Addison’s disease. The 
presence of either adrenocortical autoantibodies (ACA) or 
21-hydroxylase autoantibodies in this subgroup represents 
a good marker of developing subsequent Addison’s 
disease, which was found to be greater in coexistent 
hypoparathyroidism than either type 1 diabetes mellitus and/
or autoimmune thyroid disease.18 However, the presence 
of either circulating ACA or 21-hydroxylase antibodies 
does not invariably indicate that adrenalitis or incipient 
hypoadrenalism will occur. For example, a baby born to a 
mother who had ACA and 21-hydroxylase autoantibodies, 
Addison’s disease and coexisting hypothyroidism (APS2) 
did not develop either clinical or subclinical hypoadrenalism 
until 34 months of age, suggesting that an additional factor 
other than positive adrenal autoantibodies is required to 
induce Addison’s disease.24 In Padua, Italy, the cumulative 
risk of developing autoimmune Addison’s disease was 
48.5% among ACA-positive subjects, identifying a subgroup 
in which screening using 250 µg ACTH stimulation test 
needs to be performed periodically.25 It has not been our 
routine practice to screen for adrenal autoantibodies in 
patients with APS without Addison’s disease, except in the 
research setting, where only 3% were found to have positive 
adrenal autoantibodies.
Aetiology
The aetiology of Addison’s disease has changed over 
time. The latter half of the 20th century has seen a decline 
of Addison’s disease attributed to tuberculosis from 33% 
to 2.6%, and the majority of cases are now thought to 
be autoimmune in origin. It is only since the discovery of 
specific adrenal autoantibodies that a definitive diagnosis of 
autoimmune Addison’s disease can be made.18 Autoimmune 
Addison’s disease is the most common form of primary 
adrenal insufficiency in Western countries, accounting 
for 68-94% of cases, even when assessment by adrenal 
autoantibody assays has occurred in excess of 10 years 
after the onset of clinical disease. In an Italian study, 70% 
of patients with previously designated idiopathic Addison’s 
disease of less than 20 years’ duration were positive for 
adrenal autoantibodies, consistent with an autoimmune 
aetiology. ACA and 21-hydroxylase autoantibodies were 
reported in up to 90% of patients with recent-onset 
autoimmune Addison’s disease, compared with 0.3% 
among healthy Italian control subjects.26 Autoimmune 
Addison’s disease may occur as an isolated condition or 
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in association with APS. In childhood, APS1 occurs in 
association with hypoparathyroidism and mucocutaneous 
candidiasis, and in adulthood APS2 occurs in association 
with type 1 diabetes mellitus and autoimmune thyroid 
disease.11 
A wide variety of infections have been thought to cause 
Addison’s disease. Of these, tuberculosis accounts for 
the majority, while systemic mycoses, e.g. histoplasmosis, 
coccidiomycosis and blastomycosis, occur relatively 
rarely.8 In most recent Western series, tuberculosis 
accounts for 15% of all Addison’s disease cases.26 Adrenal 
insufficiency secondary to histoplasmosis is extremely 
rare,27 but asymptomatic infection of the adrenal glands 
by histoplasmosis occurs more commonly and should 
be considered in the differential diagnosis of enlarged 
adrenal glands.28,29 Adrenal involvement by Cryptococcus 
neoformans, Toxoplasma gondii, Mycobacterium avium-
intracellulare and Kaposi’s sarcoma usually occurs in 
an immunocompromised state, most commonly in the 
setting of human immunodeficiency virus (HIV) infection.30 
Hyponatraemia may be falsely attributed to gastrointestinal 
involvement, particularly severe diarrhoea, rather than 
to hypoadrenalism secondary to HIV infection.31,32 In one 
study, frank hypoadrenalism in advanced HIV was reported 
as remarkably uncommon.31 End-stage acquired immune 
deficiency syndrome (AIDS)-associated opportunistic 
infections, e.g. cytomegalovirus or M. avium-intracellulare, 
may impair adrenal function by direct invasion of the 
adrenal cortex.33
The adrenal glands are frequently infiltrated by metastatic 
and lymphomatous spread from primary carcinomata of the 
lung, breast, kidney, urinary bladder, pancreas, melanomata 
and haematological malignancies, and hypoadrenalism may 
occur.34 This was recognised as early as 1855 by Addison, 
who first suggested that adrenal metastases could induce 
adrenal insufficiency, but the prevalence of hypoadrenalism 
in this context is remarkably poorly documented.35 At least 
90% of the adrenal glands need to be replaced by tumours 
in order that primary hypoadrenalism may result. Although 
it is mandatory to exclude adrenal dysfunction when 
there is computerised tomographic evidence for enlarged 
adrenal glands, normal adrenal function may persist despite 
significantly enlarged adrenal glands.36,37 Interestingly, many 
of these patients demonstrate a paradoxical supranormal 
cortisol response to ACTH stimulation testing, which 
is thought to be the result of chronic stress.38 In a cohort 
of 30 patients with advanced (stage III or IV) bronchogenic 
carcinoma not preselected for adrenal metastases, 
the prevalence of hypoadrenalism using validated 
diagnostic criteria was 6.7% (95% confidence interval 
0.8-22.1%),38 which was in contrast to the 33 % reported by 
Redman et al.39 
Adrenoleukodystrophy (ALD) is a rare X-linked condition 
(1:20 000 men) characterised by a deficiency of peroxisomal 
membrane ALD protein, which transports activated acyl-
coenzyme A derivates into the peroxisomes, where they 
are shortened by beta oxidation. The ALD protein, which 
is similar to the adenosine triphosphate (ATP)-binding 
cassette transporter superfamily of proteins, is encoded by 
the ALD gene mapped to Xq28.40 This deficiency results in 
accumulation of very long-chain fatty acids (VLCFAs) in the 
blood, adrenal glands, brain, testes and liver.41 The ensuing 
demyelination may evoke an autoimmune reaction.42 
The adrenal glands may sustain damage by VLCFA 
accumulation, inducing cell membrane microviscosity and 
subsequent alterations in ACTH action.43
The presentation of ALD may vary widely, with six distinct 
described types ranging in decreasing order of severity, down 
to asymptomatic individuals. The childhood cerebral type is 
the most devastating form. It occurs in 31-35% of patients 
with ALD and is characterised by adrenal insufficiency 
and progressive relentless neurological dysfunction, often 
presenting with cognitive and gait disturbances, evolving to 
a vegetative state within two to four years.44,45 The adolescent 
and adult cerebral form occurs in 6-12% of patients with 
ALD and resembles the childhood type in which spinal cord, 
peripheral nerve and psychiatric symptoms predominate. 
However, the progression of the adolescent and adult 
cerebral form is far slower than that of the childhood 
cerebral form. Adrenomyeloneuropathy occurs in 40-46% of 
patients with ALD, and typically the age of onset is between 
20 and 40 years of age.44-46 It has a reduced propensity to 
affect cortical function and a greater tendency to affect the 
long ascending and descending tracts of the spinal cord, 
inducing, inter alia, urinary and erectile dysfunction along 
with hypoadrenalism.47 Approximately 10-20% of X-linked 
ALD patients have primary adrenal insufficiency without 
neurological involvement, and a proportion may be entirely 
asymptomatic, despite very high levels of VLCFA. Female 
carriers may have neurological involvement as a result of 
non-random X inactivation, with a similar clinical picture to 
adrenomyeloneuropathy but a slower rate of progression 
and rare adrenal involvement.44 A proportion of patients 
with Addison’s disease due to ALD without neurological 
damage exhibit increased VLCFA, and their brothers also 
demonstrate increased VLCFA.41 Although dietary restriction 
of VLCFA, particularly hexacosanoic acid (C26:0), may 
normalise plasma VLCFA, it does not produce significant 
clinical improvement and the ongoing deterioration may be 
accounted for by an autoimmune process.42 
Sarcoidosis has previously been suggested as a cause of 
Addison’s disease. However, some reports suggest that the 
sarcoidosis may have been coincidental, as the Addison’s 
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disease coexisted with another autoimmune gland failure 
compatible with Schmidt’s syndrome.48
Triple A or Allgrove’s syndrome is an autosomal recessive 
disorder, characterised by the triad of achalasia cardia, 
alacrima and ACTH-resistant adrenocortical insufficiency. 
It is also known as achalasia-Addisonianism-alacrima 
syndrome (AAAS) and results from mutations on 
chromosome 12q13.49 Antiphospholipid syndrome may 
result in primary hypoadrenalism, either due to adrenal 
haemorrhage and subsequent haemorrhagic destruction 
following vascular occlusion of the adrenal vessels or 
secondary to anticoagulant therapy in the presence of 
antiphospholipid antibodies. Autoimmune mechanisms may 
also be causative in association with the antiphospholipid 
syndrome.50 Intra-adrenal haemorrhage may hinder normal 
steroid hormone production within the adrenal cortex, 
infrequently resulting from long-term anticoagulation 
therapy.8 Haemorrhaging of the adrenal cortices has been 
demonstrated following prophylaxis with anti-coagulation 
for joint replacements.51 It has been postulated that a 
stressed adrenal gland, that is significant ACTH stimulation, 
may be more predisposed to haemorrhage if anticoagulation 
is concurrently administered.52
Mutations in transcription factors responsible for normal 
adrenal gland development have been found to induce a 
familial syndrome of congenital adrenal hypoplasia. These 
include mutations of any of the following: DAX1 [dosage-
sensitive sex reversal, adrenal hypoplasia congenital (AHC), 
critical region on the X chromosome, gene-1, NR0B1/AHC] 
and steroidogenic factor-1 (Sf1), NR5A1 and Ad4BP.53,54 
Men with congenital adrenal hypoplasia usually present in 
infancy or early childhood with salt-losing primary adrenal 
failure, recognised by profound hyponatraemia, global 
glucocorticoid deficiency in infancy and arrested puberty 
because of associated hypogonadotropic hypogonadism.54 
Duplication of the NR0B1 induces a 46,XY disorder of sex 
development, resulting in XY “sex-reversal” women.55
An analysis of the aetiology of Addison’s disease in the 
South African cohort, using specific diagnostic criteria (Table 
I), indicated that autoimmune Addison’s disease occurred in 
more than 50%, contradicting an earlier study suggesting 
that autoimmune Addison’s disease is uncommon in 
South Africa. Despite the burden of two epidemics that 
South Africa is currently facing, tuberculosis as a cause for 
Addison’s disease was remarkably uncommon and none of 




Patients with Addison’s disease require life-long 
glucocorticoid replacement therapy. This usually takes 
the form of oral hydrocortisone, which is widely available 
in Europe, the USA, the UK and South Africa.56 The UK, 
as well as some European countries, especially Norway, 
also uses cortisone acetate, which requires conversion by 
11β-hydroxysteroid dehydrogenase type 1 for activation to 
cortisol. In instances where hydrocortisone is not available, 
prednisone and dexamethasone have been used but since 
they have long half-lives, they may result in excessive night-
time concentrations, which may be deleterious.1 
Endogenous cortisol production, determined by stable 
isotope dilution mass spectrometry in healthy individuals, is 
only 6-11 mg/m2, but the ideal hydrocortisone replacement 
dose remains to be determined.57 Suggested doses vary 
from 30 mg of hydrocortisone to as little as 12.5 mg per day, 
divided into two or three daily doses.58,59 In general, clinicians 
rely on empiric doses, which vary substantially according 
Table I: The underlying aetiology of the South African Addison’s disease cohort
Aetiology Diagnostic criteria Number (%)
Autoimmune Addison’s 
disease
Presence of 21-hydroxylase autoantibodies or aACA 74 (51)
Adrenoleukodystrophy Increased plasma bVLCFA, irrespective of autoantibody pattern 6 (4)
Tuberculosis A compatible current or past clinical history of lung, bone, pelvic, peritoneal or genitourinary tuberculosis; 
radiology compatible with tuberculosis 
11 (8)
cAIDS (related) Presence of an AIDS-defining illn ess, e.g. cytomegalovirus, Mycobacterium avium-intracellulare, 
Cryptococcus neoformans, Toxoplasmosis gondii, Kaposi’s sarcoma 
0 (0)
Other causes Malignancy (biopsy proven), sarcoidosis, iron overload 0 (0)
X-linked adrenal 
hypoplasia
Male patients with primary hypoadrenalism and salt loss in the first few weeks of life; later frequently 




Isolated glucocorticoid insufficiency but normal mineralocorticoid function; may be associated with 
alacrimia and achalasia
2 (1)
Idiopathic Adrenal autoantibody negative, normal VLCFA, no history of tuberculosis or genetic form 43 (30)
a = adrenocortical autoantibodies, b = very long-chain fatty acids, c = acquired immune deficiency syndrome, d = adrenocorticotrophic hormone
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to the practice at a particular centre. Overreplacement 
with hydrocortisone may result in accelerated bone loss, 
premature atherosclerosis and metabolic syndrome.2,60-62 
However, insufficient hydrocortisone supplementation 
results in chronic symptoms of fatigue.63 There is evidence 
to support the idea that irrespective of the modality of 
glucocorticoid replacement, patients have subjective 
impaired health quality.64 
In the South African Addison’s study, it was observed 
that several forms of glucocorticoid replacement were 
used; most patients (76%) received hydrocortisone, with 
prednisone being the next most common. Both were 
given in combination with fludrocortisone (Table II). The 
total median dose of hydrocortisone corrected for body 
surface area was 12.4 mg/m2. The number of daily doses 
of hydrocortisone also varied: 33% were receiving three 
daily doses, 52% were receiving two daily doses and 
15% were receiving a single daily dose. The proportions 
of patients using once-daily hydrocortisone, cortisone 
acetate, prednisone and dexamethasone were 12%, 66%, 
40% and 100% respectively. In addition, 38% of patients 
reported having had at least one lifetime Addisonian crisis, 
and 58% of patients did not wear any form of medic alert 
identification. The only patient who used dexamethasone 
as replacement therapy was receiving a significantly greater 
glucocorticoid exposure than any of the other patients.
Conventional oral hydrocortisone replacement is 
nonphysiological, as it is well absorbed in the small and 
large intestines, inducing high peaks that are followed by 
rapid elimination. The resultant intermittent low trough levels 
require two to three doses per day. In addition, because of 
interindividual differences in the absorption and metabolism 
of hydrocortisone, uniform doses may not be appropriate 
for every patient with Addison’s disease. Irrespective of the 
modality of glucocorticoid replacement,65 normal physiology 
is not restored.63 Consequently, there is ongoing research 
to improve hydrocortisone replacement by prolonging its 
bioavailability.66
Cardiovascular disease has been linked to increased 
cortisol levels. Hypertension, increased heart rate, 
increased total cholesterol and low-density lipoprotein 
cholesterol, increased fasting insulin and increased glucose 
have all been reported to correlate with endogenous cortisol 
levels.67 Of concern is the fact that the South African 
Addison study has revealed a significant atherogenic profile 
among patients. Awareness that these patients may have a 
tendency to abnormal lipid profiles is required, so that this 
aspect of patient care is also addressed. 
Monitoring of glucocorticoid therapy
In patients with hypoadrenalism, the most significant barrier 
to monitoring therapy with glucocorticoids is that no single 
test exists that reliably reflects adequacy, overreplacement 
or underreplacement. While the 24-hour urine cortisol and 
plasma ACTH are unreliable in assessing adequacy of 
glucocorticoid replacement, plasma cortisol day curves 
have been used, but they require frequent blood sampling 
and admission to hospital.68 As salivary cortisol is easily 
accessible and correlates well with plasma cortisol, it 
represents an attractive alternative to plasma cortisol 
measurements. Both, however, demonstrate substantial 
variability.69 Both plasma and salivary cortisol monitoring 
have limited potential to guide dosing replacement therapy. 
There are no specific recommendations about the frequency 
of monitoring either plasma or salivary cortisol. 
The value of clinical assessment should be emphasised, 
since a structured scoring system correlated with plasma 
cortisol concentrations. For each of the clinical features (10 
items) that suggested overreplacement, one score point 
was added, and for each of the features that suggested 
underreplacement, a point was subtracted. An arbitrary 
score of between -2 and 2 was considered to be well 
replaced. Fatigue or loss of energy, nausea, weight loss, 
hyperpigmentation, hypoglycaemia, hyponatraemia and 
hyperkalaemia suggest underreplacement, while insomnia, 
recurrent infections, increased appetite, weight gain, 
glucose, hyperglycaemia, hypernatraemia, hypokalaemia 
and elevated blood pressure suggest overreplacement. For 
the entire scoring system and its correlation with plasma 
Table II: Glucocorticoid replacement therapy in South African Addison’s disease patients [total number of patients 148; data missing from 22 
untraceable patients (15%)]. Equivalent doses derived from Meikle and Tyler.64
Preparation Number (%) Median daily dose 
(aIQR)
bETDHD corrected for body surface 
area; mg/kg (IQR)
ETDHD corrected for body weight; 
mg/kg (IQR)64


















Dexamethasone 1 (0.7) 5 1.31 62
a = interquartile range, b = equivalent total daily hydrocortisone dose
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cortisol, the reader is referred to the paper by Arlt et al.70 
Close attention to clinical symptoms and signs indicative 
of either under- or overreplacement may be helpful in 
adjusting dose.
Recent developments in hydrocortisone 
replacement therapy
Newer formulations of hydrocortisone, focussing on 
delayed absorption, are being developed to provide a more 
physiological glucocorticoid exposure for patients requiring 
such therapy. 71 These are not yet available in South Africa.
Hydrocortisone during periods of stress 
At present there is insufficient scientific evidence to 
guide current practice in this area, and the standard 
recommendations are based on expert opinion.1 For 
example, a Cochrane review showed inadequate evidence 
to support or refute the use of supplemental perioperative 
steroids in surgical patients with adrenal insufficiency, and 
indicated that the maintenance dose may be sufficient.72 
Until further evidence is acquired, it would be best practice 
to escalate the glucocorticoid dose perioperatively.
Current recommendations are as follows:
• At least a doubling of the dose of hydrocortisone is 
warranted in most mild illnesses.
• In life-threatening situations, the dose of 
hydrocortisone should be increased to 100 mg, 
three times daily, but this may be reduced gradually, 
depending on a favourable patient response following 
surgery.
Mineralocorticoid replacement 
Mineralocorticoids are essential for the reversal of 
aldosterone deficiency. Assessment of mineralocorticoid 
adequacy is possible by evaluating plasma sodium, 
potassium and renin activity assays. An elevated plasma 
renin activity in an Addison’s patient may indicate 
inadequate mineralocorticoid substitution, while elevated 
blood pressure, peripheral oedema and sodium retention 
may indicate overreplacement. The usual dose of 9-alpha-
flouro-hydrocortisone is between 50 µg and 200 µg per 
day. Patients are at risk of developing hyperkalaemia and 
hypotension should this be discontinued.20
Conclusion
Enhanced awareness of Addison’s disease is warranted, 
since prompt institution of replacement therapy is 
potentially life-saving. Autoimmune Addison’s disease is 
the most common underlying aetiology in South Africa, 
despite the very high background prevalence of HIV and 
tuberculosis. Available forms of glucocorticoid replacement 
are nonphysiological and novel forms of therapy are in 
development. As patients with Addison’s disease may be 
at increased risk of cardiovascular disease as a result of 
atherogenic lipid profiles, surveillance of dyslipidaemia and 
preparedness to institute appropriate therapy are warranted.
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